Medtronic stock reaction to new CE Mark indication

Medtronic (MDT) stock is in focus after the company received an expanded CE Mark indication for its Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias.

The device is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter with CE Mark for ventricular ablation. It also holds U.S. FDA Breakthrough Device Designation, with a pivotal trial now enrolling patients.

Against this regulatory backdrop, Medtronic’s 1-day share price return of 1.44% and 90-day share price return of 14.46% suggest momentum has picked up recently, even as the year-to-date share price return has declined 9.26% and the 5-year total shareholder return is down 20.57%.

If this kind of medtech progress interests you, it may be worth broadening your watchlist with other healthcare AI opportunities using our screener of 43 healthcare AI stocks

For Medtronic, the recent bounce sits against weaker longer term returns, which raises a simple question. Is the latest move a catch up to business fundamentals, or just a swing in sentiment ahead of where valuation sits next?

Most Popular Narrative: 3.6% Undervalued

Medtronic is trading at $87.16 compared with a fair value narrative of $90.37. That small gap is where the long term story starts to matter.

Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer. Functional and technical analysis showed Medtronic plc to be a good addition for the longer term. Actual indicators for this moment: P/E fwd ~13.5, PEG ~1.6, Debt/Equity ~57%, EPS ~11%, Payout ~76%, and Operational Cash Flow approx. $7.3 billion. MACD above signal line, RSI 54.26, MOM and OBV positive. Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio. Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable. My investment horizon is 5 to 10 years. Medtronic plc is not spectacular in its growth but does grow over the long term. Medtronic plc is a dividend aristocrat. The number of years of dividend growth is 50 years. I cautiously bought a small group of 5 shares to monitor it more closely and potentially invest further. The healthcare weighting in my portfolio is now 2%.

This narrative, according to Silvester, leans heavily on steady earnings, solid cash generation and a long dividend record. Curious which growth and margin assumptions sit behind that $90.37 fair value and 3.6% discount? The full breakdown shows how those inputs are combined into a long term view of Medtronic.

Result: Fair Value of $90.37 (UNDERVALUED)

However, investors still need to watch for weaker long term share returns and any slowdown in Medtronic revenue or net income growth that challenges the steady earnings story.

Next Steps

If the mix of recent news and longer term returns around Medtronic feels mixed, now is the time to review the details yourself and pressure test the assumptions. To understand what the market currently sees as the upside, take a closer look at the 5 key rewards

Looking for more investment ideas beyond Medtronic?

Do not stop with Medtronic. Fresh ideas can reshape your portfolio, and skipping them now could mean missing opportunities that match your goals more closely.

• Hunt for quality at a discount by scanning companies flagged as 51 high quality undervalued stocks that pair fundamentals with appealing pricing.
• Strengthen your income stream by reviewing businesses highlighted as 8 dividend fortresses that focus on higher-yield payouts.
• Reduce portfolio stress by checking out stocks identified through the 78 resilient stocks with low risk scores that score well on resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.